Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolismStephen Jun Fei Chong, Shazib Pervaiz, Mary C. Collins et al.|Nucleic Acids Research|2020Cited by 63
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignanciesStephen Jun Fei Chong, Matthew S. Davids, Fen Zhu et al.|Journal of Clinical Investigation|2023Cited by 43
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Yifan Zhai, Zi Chen et al.|Clinical Cancer Research|2023Cited by 38
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Christoph Kornauth et al.|Blood|2021Cited by 37
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid TumorsNehal J. Lakhani, Yifan Zhai, Drew Rasco et al.|Clinical Cancer Research|2023Cited by 24